MIEBO

Growth

perfluorohexyloctane

NDAOPHTHALMICSOLUTION/DROPS
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
6

Mechanism of Action

Perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. The exact mechanism of action for MIEBO in DED is…

Pharmacologic Class:

Semifluorinated Alkane

Clinical Trials (5)

NCT07111013Phase 3Withdrawn

A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease

Started Dec 2025
0
Dry Eye Disease
NCT07054606Phase 4Completed

A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear

Started Jul 2025
104 enrolled
Dry Eye
NCT06565650Phase 4Active Not Recruiting

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

Started Jul 2024
216 enrolled
Dry Eye
NCT06346340Phase 4Completed

A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy

Started Apr 2024
97 enrolled
Dry Eye
NCT06309953Phase 4Completed

A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

Started Feb 2024
99 enrolled
Dry Eye

Loss of Exclusivity

LOE Date
Jun 21, 2037
137 months away
Patent Expiry
Jun 21, 2037
Exclusivity Expiry
May 18, 2028

Patent Records (5)

Patent #ExpiryTypeUse Code
10058615
Sep 12, 2033
U-1900
10369117
Sep 12, 2033
U-1900
10449164
Sep 12, 2033
U-1900
10576154
Oct 1, 2035
U-1900
11357738
Sep 29, 2036
Product